Disease reactivation after switching from natalizumab to daclizumab

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

(2016) Peter Alping et al.   ANNALS OF NEUROLOGY

Disease activity return after natalizumab cessation in multiple sclerosis

(2016) Maria Rasenack et al.   Expert Review of Neurotherapeutics

Disease activity return after natalizumab cessation in multiple sclerosis

(2016) Maria Rasenack et al.   Expert Review of Neurotherapeutics

Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis

(2015) Pietro Iaffaldano et al.   BRAIN

Severe disease reactivation in four patients with relapsing–remitting multiple sclerosis after fingolimod cessation

(2015) Benjamin Berger et al.   JOURNAL OF NEUROIMMUNOLOGY

Switching from natalizumab to fingolimod

(2015) Ludwig Kappos et al.   NEUROLOGY

Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment

(2015) Simon Faissner et al.   Therapeutic Advances in Neurological Disorders

Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients

(2014) Per Soelberg Sorensen et al.   JOURNAL OF NEUROLOGY

Fingolimod after natalizumab and the risk of short-term relapse

(2014) V. G. Jokubaitis et al.   NEUROLOGY

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

(2014) R. J. Fox et al.   NEUROLOGY

Switching From Natalizumab to Fingolimod in Multiple Sclerosis

(2014) Mikael Cohen et al.   JAMA Neurology